期刊文献+

泮托拉唑和雷贝拉唑对双联抗血小板治疗效应的影响 被引量:10

Effects of Pantoprazole and Rabeprazole on the Effect of Antiplatelet Dual Therapy
在线阅读 下载PDF
导出
摘要 目的观察泮托拉唑和雷贝拉唑对急性冠脉综合征患者双联抗血小板治疗效应的影响。方法急性冠脉综合征患者352例,随机分为泮托拉唑组112例,3组均给予泮托拉唑40 mg·d-1,po;雷贝拉唑组119例,给予雷贝拉唑10 mg·d-1,po,对照组121例,不加用质子泵抑制药。3组均常规给予β-受体阻断药、血管紧张肽转化酶抑制药、硝酸酯类及他汀类药物治疗,并进行双联抗血小板治疗。检测用药前和用药后1个月血小板反应指数,并随访12个月,比较3组再发心血管事件和消化道不良反应的发生率。结果用药1个月后,3组血小板反应指数均较用药前明显降低(P<0.05),雷贝拉唑组与其他两组比较差异有统计学意义(P<0.05)。随访3个月表明,雷贝拉唑组再发心血管事件高于泮托拉唑组和对照组(P<0.05);随访12个月则3组的心血管事件发生差异无统计学意义(P>0.05),消化道不良反应的发生率分别为7.56%,8.93%,37.19%(P<0.05)。结论急性冠脉综合征患者在双联抗血小板治疗同时加用泮托拉唑对氯吡格雷抗血小板疗效的影响较雷贝拉唑小。 Objective To investigate the influence of pantoprazole and rabeprazole on the effect of antiplatelet dual therapy in patients with acute coronary syndrome ( ACS ). Methods Three hundred and fifty-two patients with ACS were randomly divided into pantoprazole group (40 mg · d-1, n= 112), rabeprazole group (10 mg · d-1, n= 119) and control group (no PPI, n= 121 ). All the patients received standard therapy including beta receptor blockers, angiotensin-converting enzyme inhibitors, nitrates, and statins. The platelet reactivity index before and 1 month after the treatment was calculated, the recurrence of cardiovascular events (CVEs) and gastrointestinal adverse reactions (GARs) after a follow-up for 12 months were investigated. Results The platelet reactivity index after 1 month treatment was significantly lower than that before the treatment in each group (P〈0.05). There was a significant difference in platelet reactivity index between rabeprazole group and other groups after 1 month treatment (P〈0.05). The incidence of CVEs in rabeprazole group was 13.45% , higher than that in pantoprazole group and control group after a follow-up for 3 months (P〈0.05). There was no difference of the CVEs in each group after a follow-up for 12 months. The GARs of PPI groups were lower than that of control group after a follow-up for 3 months and 12 months (7.56% , 8.93%, 37.19% respectively, P〈0.05 ). Conclusion The influence of PPI on the antiplatelet effect of clopidogrel in patients with ACS is less with pantoprazole than rabeprazole.
出处 《医药导报》 CAS 北大核心 2013年第6期738-741,共4页 Herald of Medicine
关键词 泮托拉唑 雷贝拉唑 氯吡格雷 血小板反应指数 心血管事件 消化道不良反应 Pantoprazole Rabeprazole Clopidogrel Platelet reactivity index Cardiovascular event Gastrointestinal adverse reaction
  • 相关文献

参考文献18

  • 1ANDERSON J L,ADAMS C D,ANTMAN E M,et al. ACC/AHA 2007 guidelines for the management of patients withunstable angina/non-ST-elevation myocardial infarction[J]. J Am Coll Cardiol,2007,50(7) :151-157.
  • 2急性冠脉综合征非血运重建患者抗血小板治疗中国专家共识[R].北京:人民卫生出版社,2009.182-183.
  • 3ACCF/ACG/AHA. 2008 expert consensus document on red-ucing the gastrointestinal risk of antiplatelet therapy andNSAID use,a report of the American College of CardiologyFoundation Task Force on Clinical Expert ConsensusDocument [ J]. Circulation ,2008 ,118(18) : 1894-1909.
  • 4SMALL D S,FARID N A,PAYNE C D,et al. Effects of theproton pump inhibitor lansoprazole on the pharmacokineticsand pharmacodynamics of prasugrel and clopidogrel [ J]. JClin Pharm,2008 ,48(4) :475-484.
  • 5SHI S,KLOLZ U. Proton pump inhibitors:an update of theirclinical use and pharmacokinetics [ J]. Eur J ClinPharmacol,2008,64(10) :935-951.
  • 6GILARD M,ARNAND B,C0MILY J,et al. Influence of om-eprazole on the antiplatelet action of clopidogrel assoc iatedwith aspirin : the randomized, double-blind OCLA(Omeprazole Clopidogrel Aspirin ) study. [ J] J Am CollCardiol,2008,51(3) :256-260.
  • 7PEZALLA E,DAY D,PULLIADATH I . Initial assessmentof clinical impact of a drug interaction between clopidogreland proton pump inhibitors [ J]. J Am Coll Cardiol,2008,52(12) :1037-1040.
  • 8JUURLINK D N,GOMES T,KO D T, et al. A population-based study of the drug interaction between proton pumpinhibitors and clopidogrel[ J]. CMAJ,2009,180 (7) :713-718.
  • 9HO P M,MADDOX T M, WANG L, et al. Risk of adverseoutcomes associated with concomitant use of clopidogrel andproton pump inhibitors following acute coronary syndrome[J]. JAMA,2009,301 (9) :937-944.
  • 10SILLER-MATULA J M,SPIEL A O,LANG M,et al. Effectsof pantoprazole and esomeprazole on platelet inhibition byclopidogrel[ J]. Am Heart J,2009,157( 1 ) :1-5.

二级参考文献47

  • 1Von Beckerath N.,Kastrati A.,Wieczorek A.,吴超能.不同剂量(150mg/d与75mg/d)氯吡格雷治疗30d对患者血小板聚集的影响:随机、双盲研究[J].世界核心医学期刊文摘(心脏病学分册),2007(12):39-40. 被引量:2
  • 2刘继文,程晓曙.氯吡格雷抵抗[J].国际心血管病杂志,2006,33(1):48-51. 被引量:4
  • 3[2]Geiger J,Teichmann L,Grossmann R,et al.Monitoring of Clopidogrel Action:Comparison of Methods[J].Clinical Chemistry.2005,51 (6):957~965.
  • 4[3]Schwarz UR,Geiger J,Walter U,et al.Flow cytometric analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets[J].Thromb Haemost,1999,82:1145~1152.
  • 5[4]Barragan P,Bouvier JL,Roquebert PO,et al.Resistance to thienopyridines:clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phesphoprotein phesphorylation[J].Catheter Cardiovasc Intorv,2003,59:295~302.
  • 6[5]Aleil B,Ravanat C,Cazenave JP,et al.Flow cytometric analysis intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases[J].J Thromb Haemost,2005,3(1):85~92.
  • 7KUNAPULI S P, DORSAM R T, KIM S, et al. Platelet purinergic receptors [ J ]. Curr Opin Pharmacol , 2003,3 (1) :175-180.
  • 8WIVIOTT S D, ANTMAN E M. Clopidogrel resistance:a new chapter in a fastmoving story [ J ]. Circulation, 2004, 9( 13 ) :3064-3067.
  • 9SLOTTOW T P, BONELLO L, GAVINI R, et al. Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting atent thrombosis [ J]. Am J Cardiol,2009,104 ( 3 ) :525-530.
  • 10SEREBRUANY V, CHERALA G, WOLLIAMS C, et al. Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance" [J]. Am Heart J, 2009,158(8) :925-932.

共引文献17

同被引文献89

引证文献10

二级引证文献55

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部